Her areas of responsibility will be taken over by other members of Executive
Management. As from today:
Corporate People & Organisation and Business Assurance report to Lars
Fruergaard Jørgensen
Corporate Stakeholder Engagement reports to Jakob Riis
Corporate Communications reports to Lars Rebien Sørensen.
Commenting on the changes, Lars Rebien Sørensen, CEO, says: "I would like to thank Lise for her many contributions to Novo Nordisk during her impressive career in the company. Of special note is her leadership in driving the company's strategy within sustainable development, corporate branding and public affairs, which has earned Novo Nordisk recognition as a respected global business. I wish her the best of luck in the future."
Lise Kingo says: "I have really enjoyed being part of Novo Nordisk throughout my career, not least during my time as a member of its Executive Management. It has been a fantastic journey and I wish the company and my colleagues all the best in their onward journey. This is the beginning of a new chapter in which I plan to utilise my experience and insights in boards of companies and organisations internationally."
Following the above-mentioned changes, Novo Nordisk's Executive Management is now
composed as follows:
Product Supply.
Novo Nordisk A/SInvestor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 72 / 2014
Page 2 of 2
Jesper Brandgaard, executive vice president and CFO (chief financial officer), responsible for Finance, Legal, and Investor Relations. Lars Fruergaard Jørgensen, executive vice president, responsible for Corporate IT, Corporate Quality, Corporate Development, Corporate People & Organisation and Business Assurance. Jakob Riis, executive vice president, responsible for Marketing, Medical Affairs andCorporate Stakeholder Engagement.
Mads Krogsgaard Thomsen, executive vice president and chief science officer, responsible for Research, Development and Regulatory Affairs.Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately
41,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.
Further informationMedia: | ||
Mike Rulis | +45 3079 3573 | mike@novonordisk.com |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 72 / 2014
distributed by |